Q-omics provides the consensus-scored DCST1 profile across patient tissues and cancer cell-line models. DCST1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, DCST1 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, DCST1 RNA expression shows 18,369 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, BLCA, and UVM as cancer lineages where DCST1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCST1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCST1 survival associations across molecular data types. DCST1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCST1 RNA expression–survival associations across cancer types. High DCST1 expression shows unfavorable associations in KIRC, KIRP, COAD, LGG and LIHC, but favorable associations in HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for DCST1 RNA expression.
This table summarizes DCST1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for DCST1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCST1 shows higher tumor expression in BLCA, THCA, LUAD, LIHC, KIRC and LUSC. The BLCA box plot shows higher DCST1 RNA expression in tumor versus normal tissue (log2 FC = +0.518, t-test p < 0.001).
This table shows molecular features associated with DCST1 in patient tissues and cancer cell lines. In patient samples, DCST1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCST1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SOFT_TISSUE.
